Cytotoxicity and antiangiogenesis by fibroblast growth factor 2–targeted Ad-TK cancer gene therapy

Authors

  • Koichiro Saito MD,

    1. Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
    Search for more papers by this author
  • Khurram Khan MD,

    1. Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
    Search for more papers by this author
  • Barbara Sosnowski PhD,

    1. Tissue Repair Company, San Diego, California, U.S.A.
    Search for more papers by this author
  • Daqing Li MD,

    Corresponding author
    1. Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
    • Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, 3400 Spruce St, Ravdin 5, Philadelphia, PA 19104
    Search for more papers by this author
  • Bert W. O'Malley Jr. MD

    Corresponding author
    1. Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, U.S.A.
    • Department of Otorhinolaryngology–Head and Neck Surgery, University of Pennsylvania School of Medicine, 3400 Spruce St, Ravdin 5, Philadelphia, PA 19104
    Search for more papers by this author

  • Part of this study was presented at the 97th annual meeting of the American Association for Cancer Research, Washington, D.C., U.S.A., April 1–5, 2006 and at the annual meeting of the American Academy of Otolaryngology–Head and Neck Surgery Foundation, Toronto, Ontario, Canada, September 17–20, 2006.

Abstract

Objectives:

Human head and neck squamous cell carcinoma (HNSCC) in addition to lung, skin, ovarian, and other cancers overexpress fibroblast growth factor (FGF) receptors on both individual tumor cells and endothelial cells within the tumor microenvironment. The purpose of this study was to investigate whether FGF2-targeted gene therapy could redirect adenoviral vectors encoding the herpes simplex virus thymidine kinase gene (Ad-TK) to FGF receptors on tumor and endothelial cells with the intent of improving both the efficiency of transgene expression and the antitumor response.

Study Design and Methods:

An Ad-TK vector consisting of a conjugate of FGF2 linked to a Fab′ fragment against the adenoviral knob region was directly delivered to human HNSCC xenograft tumors in nude mice, which were subsequently dosed with ganciclovir. Tumor specimens were assessed for herpes simplex virus thymidine kinase (HSV-tk) transgene mRNA expression, FGF1/2 receptor expression, terminal deoxynucleotidyl transferase biotin–deoxy uridine triphosphate nick end labeling assay for apoptosis, CD31 immunohistochemistry to estimate tumor microvessel density, and tumor volume change.

Results:

FGF2-retargeted Ad-TK gene therapy demonstrated significant increases in both HSV-tk mRNA expression and cellular apoptosis levels, and a significant decrease in tumor volume size compared with all other groups. Furthermore, microvessel density was significantly lower in the FGF2-retargeted Ad-TK group, indicating a strong antiangiogenesis effect.

Conclusions:

These data suggest that FGF2-retargeted Ad-TK produces a combination of expected direct antitumor cytotoxicity and a newly reported antiangiogenesis effect that could prove promising as a novel therapeutic approach in the treatment of FGF receptor–expressing cancers. Laryngoscope, 2009

Ancillary